Pharmacology of airway inflammation in asthma and COPD.

[1]  R. Schleimer,et al.  An overview of glucocorticoid anti-inflammatory actions , 2005, European Journal of Clinical Pharmacology.

[2]  A. Yorgancioglu,et al.  Prevalence of Chlamydia pneumoniae specific antibodies in different clinical situations and healthy subjects in Izmir, Turkey , 1998, European Journal of Epidemiology.

[3]  H. Nelson,et al.  Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. , 2003, The Journal of allergy and clinical immunology.

[4]  D. Rogers.  Airway hypersecretion in allergic rhinitis and asthma: New pharmacotherapy , 2003, Current allergy and asthma reports.

[5]  I. Adcock.  Glucocorticoids: New mechanisms and future agents , 2003, Current allergy and asthma reports.

[6]  P. Barnes.  Theophylline: new perspectives for an old drug. , 2003, American journal of respiratory and critical care medicine.

[7]  A. Burks,et al.  Effect of anti-IgE therapy in patients with peanut allergy. , 2003, The New England journal of medicine.

[8]  L. Fabbri,et al.  Predominant emphysema phenotype in chronic obstructive pulmonary disease patients , 2003, European Respiratory Journal.

[9]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[10]  L. Corbetta,et al.  Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[11]  F. Sinigaglia,et al.  Chemokine receptors in inflammation: an overview. , 2003, Journal of immunological methods.

[12]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[13]  W. Henderson,et al.  CCR8 Is Not Essential for the Development of Inflammation in a Mouse Model of Allergic Airway Disease , 2003, The Journal of Immunology.

[14]  P. Barnes.  New treatments for chronic obstructive pulmonary disease. , 2001, Current opinion in pharmacology.

[15]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[16]  E. Gelfand.  Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. , 2002, The American journal of medicine.

[17]  L. Boulet,et al.  Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids , 2002, European Respiratory Journal.

[18]  R. Dahl,et al.  Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study , 2002, European Respiratory Journal.

[19]  M. Giembycz.  4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered? , 2002, Trends in pharmacological sciences.

[20]  E. Raz,et al.  Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. , 2002, The Journal of allergy and clinical immunology.

[21]  A. Chuchalin,et al.  Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. , 2002, Respiratory medicine.

[22]  T. Torphy,et al.  What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases. , 2002, Pulmonary pharmacology & therapeutics.

[23]  I. Hussain,et al.  Modulation of Murine Allergic Rhinosinusitis by CpG Oligodeoxynucleotides , 2002, The Laryngoscope.

[24]  M. Weisman.  What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. , 2002, The Journal of rheumatology. Supplement.

[25]  G. Berry,et al.  Antigen-specific regulatory T cells develop via the ICOS–ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity , 2002, Nature Medicine.

[26]  P. Jeffery,et al.  Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue , 2002, Thorax.

[27]  Peter Reid,et al.  Roflumilast Altana Pharma. , 2002, Current opinion in investigational drugs.

[28]  A. Buist.  Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[29]  H. Hirata,et al.  Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. , 2002, American journal of respiratory and critical care medicine.

[30]  H. Fujiwara,et al.  A non‐peptide CCR5 antagonist inhibits collagen‐induced arthritis by modulating T cell migration without affecting anti‐collagen T cell responses , 2002, European journal of immunology.

[31]  G. Trainor,et al.  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships. , 2002, Bioorganic & medicinal chemistry letters.

[32]  I. Adcock.  Role of mediators in late-phase allergic symptoms including congestion , 2002 .

[33]  J. Prandota.  Furosemide: Progress in Understanding Its Diuretic, Anti-inflammatory, and Bronchodilating Mechanism of Action, and Use in the Treatment of Respiratory Tract Diseases , 2002, American journal of therapeutics.

[34]  P. Barnes,et al.  Increased levels of the chemokines GROα and MCP-1 in sputum samples from patients with COPD , 2002, Thorax.

[35]  B. Lipworth,et al.  Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. , 2002, Chest.

[36]  I. Adcock,et al.  A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Kiniwa,et al.  Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. , 2002, International immunopharmacology.

[38]  G. Rook,et al.  Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells , 2002, Nature Medicine.

[39]  P. Barnes.  New treatments for copd , 2002, Nature Reviews Drug Discovery.

[40]  A. Pahl,et al.  Asthma therapy in the new millennium , 2002, Inflammation Research.

[41]  C. Burnouf,et al.  Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. , 2002, Current pharmaceutical design.

[42]  P. Barnes,et al.  Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[43]  L. Fabbri,et al.  Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[44]  Stephen C Lazarus,et al.  Systemic effect comparisons of six inhaled corticosteroid preparations. , 2002, American journal of respiratory and critical care medicine.

[45]  W. D. Boer.  Cytokines and therapy in COPD: A promising combination? , 2002 .

[46]  I. Hall,et al.  The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis. , 2002, Pulmonary pharmacology & therapeutics.

[47]  S. Romagnani.  Cytokines and chemoattractants in allergic inflammation. , 2002, Molecular immunology.

[48]  L. Borish.  The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[49]  D. Johns,et al.  Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma , 2002, Thorax.

[50]  I. Adcock,et al.  Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma. , 2002, Clinical immunology.

[51]  M. Adachi,et al.  Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. , 2002, Chest.

[52]  Stephen C Lazarus,et al.  Banks CORTICOSTEROIDS FOR PERSISTENT ASTHMA SIGNIFICANT VARIABILITY IN RESPONSE TO INHALED Services , 2022 .

[53]  Giembycz Ma.  Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. , 2002 .

[54]  U. Lalloo.  Symbicort: controlling asthma in adults. , 2002, Respiratory medicine.

[55]  C. Hawrylowicz,et al.  A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. , 2002, The Journal of allergy and clinical immunology.

[56]  K. Rabe,et al.  Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease , 2002, Current opinion in allergy and clinical immunology.

[57]  D. Olivieri,et al.  Eotaxin and CCR3 are up‐regulated in exacerbations of chronic bronchitis , 2002, Allergy.

[58]  P. Barnes,et al.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[59]  I. Adcock,et al.  Overview: why are corticosteroids ineffective in COPD? , 2002, Current opinion in investigational drugs.

[60]  R. Pauwels,et al.  Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[61]  K. Asadullah,et al.  SEGRAs: a novel class of anti-inflammatory compounds. , 2002, Ernst Schering Research Foundation workshop.

[62]  S. Umland,et al.  Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. , 2002, Pulmonary pharmacology & therapeutics.

[63]  T. Shimoda,et al.  Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. , 2002, Chest.

[64]  B. Lipworth,et al.  Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. , 2002, The Journal of allergy and clinical immunology.

[65]  P. Barnes.  Cytokine modulators as novel therapies for asthma. , 2002, Annual review of pharmacology and toxicology.

[66]  R. Naclerio,et al.  Antiallergic anti-inflammatory effects of H1-antihistamines in humans. , 2002, Clinical allergy and immunology.

[67]  R. Pauwels,et al.  Interleukin-4 and interleukin-5 gene expression and inflammation in the mucus-secreting glands and subepithelial tissue of smokers with chronic bronchitis. Lack of relationship with CD8(+) cells. , 2001, American journal of respiratory and critical care medicine.

[68]  S. Till,et al.  The immunomodulatory drugs cyclosporin A, mycophenolate mofetil, and sirolimus (rapamycin) inhibit allergen-induced proliferation and IL-5 production by PBMCs from atopic asthmatic patients. , 2001, Journal of Allergy and Clinical Immunology.

[69]  S. Holgate,et al.  Omalizumab, a novel anti-IgE therapy in allergic disorders , 2001, Expert opinion on biological therapy.

[70]  L. Presta,et al.  Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. , 2001, Cytokine.

[71]  R. Pauwels,et al.  Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. , 2001, European journal of pharmacology.

[72]  I. Adcock,et al.  Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. , 2001, American journal of respiratory and critical care medicine.

[73]  M. Cazzola,et al.  Comparison of the Bronchodilating Effect of Salmeterol and Zafirlukast in Combination with That of Their Use as Single Treatments in Asthma and Chronic Obstructive Pulmonary Disease , 2001, Respiration.

[74]  D. Postma,et al.  Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. , 2001, American journal of respiratory and critical care medicine.

[75]  G. Fitzmaurice,et al.  Effects of inhaled glucocorticoids on bone density in premenopausal women. , 2001, The New England journal of medicine.

[76]  R. Pauwels,et al.  Long-acting inhaled β2-agonist therapy in asthma , 2001 .

[77]  T. Sandström,et al.  Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma. , 2001, American journal of respiratory and critical care medicine.

[78]  I. Adcock,et al.  Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. , 2001, The European respiratory journal.

[79]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[80]  P. Barnes,et al.  Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids , 2001 .

[81]  T. Shoji,et al.  Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. , 2001, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[82]  G. Caramori,et al.  Cross‐talk between pro‐inflammatory transcription factors and glucocorticoids , 2001, Immunology and cell biology.

[83]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[84]  R. Martin,et al.  Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment. , 2001, Chest.

[85]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[86]  S. Yancey,et al.  Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. , 2001, Chest.

[87]  C. Brambilla,et al.  Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study , 2001, The Lancet.

[88]  A. Medvedev,et al.  β-Adrenergic Activation of p38 MAP Kinase in Adipocytes , 2001, The Journal of Biological Chemistry.

[89]  I. Adcock,et al.  Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. , 2001, American journal of respiratory and critical care medicine.

[90]  S. Rennard,et al.  Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD , 2001 .

[91]  S. Miyazaki,et al.  A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism. , 2001, The Journal of allergy and clinical immunology.

[92]  N. Inagaki,et al.  Drugs for the treatment of allergic diseases. , 2001, Japanese journal of pharmacology.

[93]  R. Aalbers,et al.  Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists , 2001, Thorax.

[94]  P. Barnes,et al.  Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial , 2001, The Lancet.

[95]  M. Neurath,et al.  Treatment of Allergic Airway Inflammation and Hyperresponsiveness by Antisense-Induced Local Blockade of Gata-3 Expression , 2001, The Journal of experimental medicine.

[96]  I. Adcock,et al.  Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[97]  R. Stockley,et al.  Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. , 2001, The European respiratory journal.

[98]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[99]  D. Mahler,et al.  Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. , 2001, The European respiratory journal.

[100]  M. Fukuoka,et al.  Effects of suplatast tosilate (IPD Capsules) on the production of active oxygen by neutrophils and of IL-8 by mononuclear cells. , 2001, International immunopharmacology.

[101]  C. Owen.  Chemokine receptors in airway disease: which receptors to target? , 2001, Pulmonary pharmacology & therapeutics.

[102]  R. Brattsand,et al.  Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. , 2001, The European respiratory journal.

[103]  R. Zuwallack,et al.  Salmeterol plus theophylline combination therapy in the treatment of COPD. , 2001, Chest.

[104]  L. Fabbri,et al.  The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. , 2001, The Journal of clinical investigation.

[105]  Vernon M. Chinchilli,et al.  Long-Acting β2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial , 2001 .

[106]  E. Israel,et al.  Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. , 2001, JAMA.

[107]  R. Aalbers,et al.  Compliance with inhaled glucocorticoids and concomitant use of long-acting beta2-agonists. , 2001, Respiratory medicine.

[108]  L. Fabbri,et al.  Cellular and structural bases of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[109]  J. Bousquet,et al.  Effects of glucocorticoids on endogenous and transcellular metabolism of eicosanoids in asthma. , 2001, The Journal of allergy and clinical immunology.

[110]  C. Baum,et al.  Malnutrition in chronic obstructive pulmonary disease: adding insult to injury. , 2001, AACN clinical issues.

[111]  S. Laufer,et al.  Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. , 2001, Pharmacological research.

[112]  M. De Salvo,et al.  In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. , 2001, Chest.

[113]  R. Zuwallack,et al.  Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary Disease , 2001 .

[114]  M. Tamm,et al.  Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. , 2001, American journal of respiratory and critical care medicine.

[115]  N. Strenzke,et al.  Effect of chloride channel blockers on anti-IgE-stimulated histamine and IL-4/IL-13 release from human basophils , 2001, Inflammation Research.

[116]  B. Lipworth,et al.  Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. , 2001, Chest.

[117]  I. Adcock,et al.  Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[118]  R. Egan,et al.  Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease , 2001, Respiratory research.

[119]  M. Sanak,et al.  Leukotriene C4 synthase polymorphism and aspirin-induced asthma. , 2001, The Journal of allergy and clinical immunology.

[120]  H. Magnussen,et al.  Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. , 2001, Pulmonary pharmacology & therapeutics.

[121]  L. Boulet,et al.  Effect of salmeterol on allergen‐induced airway inflammation in mild allergic asthma , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[122]  E. Raz,et al.  DNA‐based immunotherapeutics for the treatment of allergic disease , 2001, Immunological reviews.

[123]  K. R. Anderson,et al.  Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. , 2001, Chest.

[124]  A. Knox,et al.  Regulation of TNF‐α‐induced eotaxin release from cultured human airway smooth muscle cells by β2‐agonists and corticosteroids , 2001 .

[125]  P. Cullinan,et al.  Cyclosporin as an oral corticosteroid sparing agent in stable asthma. , 2000, The Cochrane database of systematic reviews.

[126]  Blair Jarvis,et al.  Inhaled Salmeterol , 2001, Drugs & aging.

[127]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[128]  Stephen T Holgate,et al.  Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response , 2000, The Lancet.

[129]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[130]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[131]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[132]  P. Howarth,et al.  Persistent airway T-lymphocyte activation in chronic corticosteroid-treated symptomatic asthma. , 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[133]  M. Cazzola,et al.  Additive effects of salmeterol and fluticasone or theophylline in COPD. , 2000, Chest.

[134]  E. Kerwin,et al.  Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. , 2000, The Journal of allergy and clinical immunology.

[135]  O. Civelli,et al.  Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. , 2000, Molecular pharmacology.

[136]  J C van der Wouden,et al.  Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review , 2000, Thorax.

[137]  N Franklin Adkinson,et al.  Long-term effects of budesonide or nedocromil in children with asthma. , 2000, The New England journal of medicine.

[138]  R. Martin,et al.  Substance P and its receptor neurokinin 1 expression in asthmatic airways. , 2000, The Journal of allergy and clinical immunology.

[139]  D. D'Ambrosio,et al.  Regulation of helper T cell differentiation and recruitment in airway inflammation. , 2000, American journal of respiratory and critical care medicine.

[140]  A. Kay,et al.  Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. , 2000, American journal of respiratory and critical care medicine.

[141]  M. Robuschi,et al.  Inhaled transmembrane ion transport modulators and non-steroidal anti-inflammatory drugs in asthma , 2000, Thorax.

[142]  B. Lipworth,et al.  Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. , 2000, Chest.

[143]  K. Chung,et al.  Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. , 2000, American journal of respiratory and critical care medicine.

[144]  Jilly F. Evans,et al.  Characterization of the Human Cysteinyl Leukotriene 2 Receptor* , 2000, The Journal of Biological Chemistry.

[145]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[146]  M. Sanak,et al.  Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. , 2000, American journal of respiratory cell and molecular biology.

[147]  W. Busse,et al.  Inhaled budesonide decreases airway inflammatory response to allergen. , 2000, American journal of respiratory and critical care medicine.

[148]  F. Blasi,et al.  Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[149]  E. R. Mcfadden,et al.  Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. , 2000, The Journal of allergy and clinical immunology.

[150]  B. Lipworth,et al.  Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. , 2000, Chest.

[151]  D. Theegarten,et al.  The role of chlamydia in the pathogenesis of pulmonary emphysema , 2000, Virchows Archiv.

[152]  K. Kelly,et al.  Nedocromil sodium versus sodium cromoglycate for preventing exercise-induced bronchoconstriction , 2000 .

[153]  E. Tagaya,et al.  Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study , 2000, The Lancet.

[154]  P. O'Byrne,et al.  Protective effects of fluticasone on allergen-induced airway responses and sputum inflammatory markers. , 2000, Canadian respiratory journal.

[155]  R. Egan,et al.  Control of IL-5 production by human helper T cells as a treatment for eosinophilic inflammation: comparison of in vitro and in vivo effects between selective and nonselective cytokine synthesis inhibitors. , 2000, The Journal of allergy and clinical immunology.

[156]  J. Drazen,et al.  5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. , 2000, The Journal of allergy and clinical immunology.

[157]  I. Adcock,et al.  Molecular mechanisms of glucocorticosteroid actions. , 2000, Pulmonary pharmacology & therapeutics.

[158]  S. Shrewsbury,et al.  Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.

[159]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[160]  H. Simon,et al.  Treatment with IFN-a in corticosteroid-unresponsiveasthma , 2000 .

[161]  S. Sethi.  Bacterial infection and the pathogenesis of COPD. , 2000, Chest.

[162]  M. Sears,et al.  Chlamydia pneumoniae serological status is not associated with asthma in children or young adults. , 2000, International journal of epidemiology.

[163]  A. Knox,et al.  Synergistic Inhibition by β2-Agonists and Corticosteroids on Tumor Necrosis Factor- α –Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells , 2000 .

[164]  R. Pauwels,et al.  A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. , 2000, American journal of respiratory and critical care medicine.

[165]  G. Anderson,et al.  Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. , 2000, American journal of respiratory and critical care medicine.

[166]  R. Djukanović,et al.  Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma: effect on mucosal inflammation and in vitro sensitivity to glucocorticoids of mitogen-induced T-cell proliferation. , 2000, The European respiratory journal.

[167]  Barnes Pj.  Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000 .

[168]  D. Strachan,et al.  Chlamydia pneumoniae serology, lung function decline, and treatment for respiratory disease. , 2000, American journal of respiratory and critical care medicine.

[169]  H. Nelson,et al.  Lack of correlation between Chlamydia pneumoniae antibody titers and adult-onset asthma. , 2000, The Journal of allergy and clinical immunology.

[170]  P. Barnes,et al.  Mechanisms in COPD: differences from asthma. , 2000, Chest.

[171]  E. Bronsky,et al.  Oral Montelukast Compared with Inhaled Salmeterol To Prevent Exercise-Induced Bronchoconstriction , 2000, Annals of Internal Medicine.

[172]  H. Davies,et al.  Methotrexate as a steroid sparing agent for asthma in adults. , 1998, The Cochrane database of systematic reviews.

[173]  T. Shimizu,et al.  Leukotriene-B4 receptor and signal transduction. , 2000, Ernst Schering Research Foundation workshop.

[174]  I. Danta,et al.  Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. , 2000, American journal of respiratory and critical care medicine.

[175]  P. O'Byrne,et al.  The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma. , 2000, American journal of respiratory and critical care medicine.

[176]  J. Fahy,et al.  Low- and high-dose fluticasone propionate in asthma; effects during and after treatment. , 2000, The European respiratory journal.

[177]  B. Lipworth,et al.  A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. , 2011, The Journal of allergy and clinical immunology.

[178]  F. Annunziato,et al.  Phosphorothioate oligodeoxynucleotides promote the in vitro development of human allergen-specific CD4+ T cells into Th1 effectors. , 1999, Journal of immunology.

[179]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[180]  E. Nussbaum,et al.  Immunosuppressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[181]  B. Lipworth,et al.  Lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. , 1999, American journal of respiratory and critical care medicine.

[182]  P. Barnes.  Therapeutic strategies for allergic diseases , 1999, Nature.

[183]  N. Bodor,et al.  Recent advances in retrometabolic design approaches. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[184]  F. Thien,et al.  An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. , 1999, American journal of respiratory and critical care medicine.

[185]  W. Maziak,et al.  Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[186]  J. Carlstedt-Duke.  Glucocorticoid Receptor β: View II , 1999, Trends in Endocrinology & Metabolism.

[187]  G. Chrousos,et al.  Glucocorticoid Receptor β: View I , 1999, Trends in Endocrinology & Metabolism.

[188]  A. Chuchalin,et al.  Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. , 1999, The Journal of allergy and clinical immunology.

[189]  K. Chung,et al.  Cytokines in asthma , 1999, Thorax.

[190]  D. Postma,et al.  Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. , 1999, American journal of respiratory and critical care medicine.

[191]  K. Satoh,et al.  Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. , 1999, The European respiratory journal.

[192]  J. Lötvall,et al.  Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. , 1999, American journal of respiratory and critical care medicine.

[193]  L. Boulet,et al.  Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. , 1999, The European respiratory journal.

[194]  S. Holgate,et al.  IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. , 1999, Journal of immunology.

[195]  P. Sterk,et al.  Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. , 1999, American journal of respiratory and critical care medicine.

[196]  P. O'Byrne,et al.  An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. , 1999, American journal of respiratory and critical care medicine.

[197]  A. Zwinderman,et al.  Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma , 1999, Thorax.

[198]  K. Umesono,et al.  Redox-dependent Regulation of Nuclear Import of the Glucocorticoid Receptor* , 1999, The Journal of Biological Chemistry.

[199]  Leinonen,et al.  Asthma, atopy and Chlamydia pneumoniae antibodies in adults , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[200]  J. Vandenbroucke,et al.  Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. , 1999, American journal of respiratory and critical care medicine.

[201]  F. Thien,et al.  Vascularity in asthmatic airways: relation to inhaled steroid dose. , 1999, Thorax.

[202]  Lynn Wei,et al.  Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma , 1999, Annals of Internal Medicine.

[203]  T. Mosmann,et al.  Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. , 1999, Journal of immunology.

[204]  D. Umetsu,et al.  The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. , 1999, The Journal of allergy and clinical immunology.

[205]  J. Drazen,et al.  Genetic Determinants of 5–Lipoxygenase Transcription , 1999, International Archives of Allergy and Immunology.

[206]  E. Israel,et al.  Correction: Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. , 1999, The New England journal of medicine.

[207]  O. Eickelberg,et al.  Ligand-independent Activation of the Glucocorticoid Receptor by β2-Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and Vascular Smooth Muscle Cells* , 1999, The Journal of Biological Chemistry.

[208]  A. Zwinderman,et al.  The effect of montelukast (MK‐0476), a cysteinyl leukotriene receptor antagonist, on allergen‐induced airway responses and sputum cell counts in asthma , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[209]  P. Godard,et al.  A comparison of two long-acting P-agonists, oral bambuterol and inhaled salmeterol, in the treatment of moderate to severe asthmatic patients with nocturnal symptoms , 2004 .

[210]  P. Howarth,et al.  The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[211]  I. Pavord,et al.  Prednisone-dependent asthma: inflammatory indices in induced sputum. , 1999, The European respiratory journal.

[212]  Mutations in the human 5-lipoxygenase gene , 1999, Clinical reviews in allergy & immunology.

[213]  N. Tzanakis,et al.  Diagnosis and treatment of chronic obstructive pulmonary disease: evidence-based medicine. , 1998, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[214]  B. Lindmark.  Cardiac risks with β agonists , 1998, Thorax.

[215]  K. Chung,et al.  Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.

[216]  J. Drazen.  Leukotrienes as mediators of airway obstruction. , 1998, American journal of respiratory and critical care medicine.

[217]  I. Adcock,et al.  Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. , 1998, American journal of respiratory and critical care medicine.

[218]  J. Jenne.  Can oral β2 agonists cause heart failure? , 1998, The Lancet.

[219]  J. Oates,et al.  Salmeterol prevents aspirin-induced attacks of asthma and interferes with eicosanoid metabolism. , 1998, American journal of respiratory and critical care medicine.

[220]  Teruo Sakamoto,et al.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma , 1998, Thorax.

[221]  R. Martin,et al.  Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. , 1998, American journal of respiratory and critical care medicine.

[222]  M. Sears,et al.  Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.

[223]  P. Sterk,et al.  Effects of theophylline on tolerance to the bronchoprotective actions of salmeterol in asthmatics in vivo. , 1998, American journal of respiratory and critical care medicine.

[224]  G. Town,et al.  Asthma control during long term treatment with regular inhaled salbutamol and salmeterol , 1998, Thorax.

[225]  J. Drazen,et al.  Egr-1 and Sp1 interact functionally with the 5-lipoxygenase promoter and its naturally occurring mutants. , 1998, American journal of respiratory cell and molecular biology.

[226]  E. R. Mcfadden,et al.  Effect of long-term salmeterol treatment on exercise-induced asthma. , 1998, The New England journal of medicine.

[227]  P. Barnes,et al.  Haplotype associated with low interleukin-10 production in patients with severe asthma , 1998, The Lancet.

[228]  S. Szefler,et al.  Fluticasone propionate results in improved glucocorticoid receptor binding affinity and reduced oral glucocorticoid requirements in severe asthma. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[229]  P. Clementsen,et al.  Chlamydia pneumoniae and possible relationship to asthma , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[230]  N. Dunn,et al.  Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2 agonists , 1998, Thorax.

[231]  R. Dockhorn,et al.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. , 1998, Archives of internal medicine.

[232]  H. Boushey,et al.  Effect of low-dose beclomethasone dipropionate on asthma control and airway inflammation. , 1998, The European respiratory journal.

[233]  M. Karin.  New Twists in Gene Regulation by Glucocorticoid Receptor: Is DNA Binding Dispensable? , 1998, Cell.

[234]  R. Fuller,et al.  An overview of nine clinical trials of salmeterol in an asthmatic population. , 1998, Respiratory medicine.

[235]  P. Paggiaro,et al.  Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.

[236]  S. Wenzel,et al.  New approaches to anti-inflammatory therapy for asthma. , 1998, The American journal of medicine.

[237]  S. Holgate,et al.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. , 1998, The Journal of clinical investigation.

[238]  K. Wilner,et al.  Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP-105,696 in man following single oral administration. , 1998, British journal of clinical pharmacology.

[239]  B. Davies,et al.  The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. , 1998, Respiratory medicine.

[240]  R. Panettieri,et al.  Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction In vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. , 1998, American journal of respiratory cell and molecular biology.

[241]  K. Chung,et al.  Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.

[242]  R. Sakalauskas,et al.  Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. , 1997, The European respiratory journal.

[243]  K. Chung,et al.  A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. , 1997, The New England journal of medicine.

[244]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[245]  Robert J. Lefkowitz,et al.  Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.

[246]  F. Blasi,et al.  Failure to detect the presence of Chlamydia pneumoniae in sarcoid pathology specimens. , 1997, The European respiratory journal.

[247]  R. Snijder,et al.  Diagnosis of Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease by micro-immunofluorescence and ELISA. , 1997, Journal of medical microbiology.

[248]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[249]  D. McDonald,et al.  Upregulation of substance P receptors in angiogenesis associated with chronic airway inflammation in rats. , 1997, The American journal of physiology.

[250]  A. Pesci,et al.  Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma. , 1997, The Journal of allergy and clinical immunology.

[251]  A Bast,et al.  Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.

[252]  D. Yates,et al.  Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. , 1997, The European respiratory journal.

[253]  A. Casalini,et al.  Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. , 1997, American journal of respiratory and critical care medicine.

[254]  J. Baker,et al.  Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. , 1997, European journal of biochemistry.

[255]  J. Bousquet,et al.  Corticosteroid reversibility in COPD is related to features of asthma. , 1997, American journal of respiratory and critical care medicine.

[256]  A. Sousa,et al.  Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. , 1997, Thorax.

[257]  S. Wenzel,et al.  The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. , 1997, Chest.

[258]  S. Durham,et al.  Effect of cyclosporin A on the allergen-induced late asthmatic reaction. , 1997, Thorax.

[259]  M. Leinonen,et al.  Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease , 1997, Epidemiology and Infection.

[260]  E. Silverman,et al.  Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. , 1997, The Journal of clinical investigation.

[261]  P. Barnes,et al.  Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. , 1997, American journal of respiratory and critical care medicine.

[262]  S. Anderson,et al.  Effect of inhaled frusemide and oral indomethacin on the airway response to hypertonic saline challenge in asthmatic subjects. , 1997, Thorax.

[263]  B. Celli.  ATS standards for the optimal management of chronic obstructive pulmonary disease. , 1997, Respirology.

[264]  M. Beato,et al.  Interaction of steroid hormone receptors with the transcription initiation complex. , 1996, Endocrine reviews.

[265]  D. Yates,et al.  An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. , 1996, American journal of respiratory and critical care medicine.

[266]  P. Barnes,et al.  Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. , 1996, Thorax.

[267]  L. Dubé,et al.  Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial , 1996 .

[268]  J. Baseman,et al.  Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. , 1996, American journal of respiratory and critical care medicine.

[269]  C. Corrigan,et al.  Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. , 1996, The European respiratory journal.

[270]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[271]  I. Adcock,et al.  Glucocorticoid receptor localization in normal and asthmatic lung. , 1996, American journal of respiratory and critical care medicine.

[272]  E. Gelfand,et al.  Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. , 1996, Journal of immunology.

[273]  R. Djukanović,et al.  Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. , 1996, The European respiratory journal.

[274]  J. V. van Noord,et al.  Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. , 1996, The European respiratory journal.

[275]  S T Holgate,et al.  Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. , 1996, The Journal of allergy and clinical immunology.

[276]  N. Barnes,et al.  Can clinical response to cyclosporin in chronic severe asthma be predicted by an in vitro T-lymphocyte proliferation assay? , 1996, The European respiratory journal.

[277]  S. Wenzel,et al.  Theophylline: potential antiinflammatory effects in nocturnal asthma. , 1996, The Journal of allergy and clinical immunology.

[278]  S. Durham,et al.  Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. , 1996, The Journal of allergy and clinical immunology.

[279]  A. Norris.  Pharmacology of sodium cromoglycate , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[280]  L. Fabbri,et al.  Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution. , 1996, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[281]  D. McDonald,et al.  Sensory denervation by neonatal capsaicin treatment exacerbates Mycoplasma pulmonis infection in rat airways. , 1996, The American journal of physiology.

[282]  N. Barnes,et al.  Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. , 1996, American journal of respiratory and critical care medicine.

[283]  P. Barnes,et al.  Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.

[284]  S. Durham,et al.  Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. , 1996, American journal of respiratory and critical care medicine.

[285]  J. Murray,et al.  A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. , 1996, The Journal of allergy and clinical immunology.

[286]  C. Janson,et al.  Serology of chlamydia in relation to asthma and bronchial hyperresponsiveness. , 1996, Scandinavian journal of infectious diseases.

[287]  D. Yates,et al.  Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. , 1996, American journal of respiratory and critical care medicine.

[288]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[289]  A. Baldwin,et al.  Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.

[290]  D. Mungan,et al.  Cyclosporin in steroid dependent asthma. , 1995, Allergologia et immunopathologia.

[291]  P. Barnes,et al.  Beta-adrenergic receptors and their regulation. , 1995, American journal of respiratory and critical care medicine.

[292]  K. Sladek,et al.  Treatment of steroid-dependent bronchial asthma with cyclosporin. , 1995, The European respiratory journal.

[293]  T. Fukuda,et al.  Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. , 1995, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[294]  C. Page,et al.  Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. , 1995, The European respiratory journal.

[295]  K. Chung,et al.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. , 1995, American journal of respiratory and critical care medicine.

[296]  R. Djukanović,et al.  The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. , 1995, The European respiratory journal.

[297]  G. Cox,et al.  Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. , 1995, Journal of immunology.

[298]  J. Virchow,et al.  T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. , 1995, American journal of respiratory and critical care medicine.

[299]  N. Barnes,et al.  Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. , 1995, The European respiratory journal.

[300]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[301]  O. Kaminuma,et al.  IL-5 production by CD4+ T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. , 1995, International immunology.

[302]  C. Chavis,et al.  Enhancement of leukotriene A4 biosynthesis in neutrophils from patients with rheumatoid arthritis after a single glucocorticoid dose. , 1995, Biochemical pharmacology.

[303]  Richard J Martin,et al.  The effects of nebulized recombinant interferon-γ in asthmatic airways , 1995 .

[304]  R. Schleimer,et al.  The effects of glucocorticoids on human eosinophils. , 1994, The Journal of allergy and clinical immunology.

[305]  D. McDonald,et al.  Dexamethasone and oxytetracycline reverse the potentiation of neurogenic inflammation in airways of rats with Mycoplasma pulmonis infection. , 1994, American journal of respiratory and critical care medicine.

[306]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[307]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[308]  Hahn Dl.  Infection as a cause of asthma. , 1994 .

[309]  O. Kaminuma,et al.  Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. , 1994, International archives of allergy and immunology.

[310]  K. Oizumi,et al.  Association of Mycoplasma pneumoniae antigen with initial onset of bronchial asthma. , 1994, American journal of respiratory and critical care medicine.

[311]  P. Howarth,et al.  Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. , 1994, American journal of respiratory cell and molecular biology.

[312]  C. Page,et al.  Anti-inflammatory effects of low-dose oral theophylline in atopic asthma , 1994, The Lancet.

[313]  J. Oates,et al.  Effect of oral prednisone on airway inflammatory mediators in atopic asthma. , 1994, American journal of respiratory and critical care medicine.

[314]  S. McColl,et al.  Granulocyte/macrophage colony-stimulating factor stimulates the expression of the 5-lipoxygenase-activating protein (FLAP) in human neutrophils , 1994, The Journal of experimental medicine.

[315]  H. Taniguchi,et al.  Reduction of the severity of bronchial hyperresponsiveness by the novel leukotriene antagonist 4-oxo-8-[4-(4-phenyl-butoxy)benzoylamino]-2- (tetrazol-5-yl)-4H-1-benzopyran hemihydrate. , 1994, Arzneimittel-Forschung.

[316]  G. Chiappara,et al.  Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. , 1994, The European respiratory journal.

[317]  B. Li,et al.  The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. , 1994, The Journal of allergy and clinical immunology.

[318]  P. Howarth,et al.  Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. , 1994, American journal of respiratory and critical care medicine.

[319]  R. de Caterina,et al.  Macrophage-specific eicosanoid synthesis inhibition and lipocortin-1 induction by glucocorticoids. , 1993, Journal of applied physiology.

[320]  R. M. Refini,et al.  Potentiation of the antireactive, antiasthmatic effect of inhaled furosemide by inhaled lysine acetylsalicylate , 1993, Allergy.

[321]  P. Barnes,et al.  Differential down-regulation of pulmonary β1- and β2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline , 1993 .

[322]  H. Magnussen,et al.  Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. , 1993, Chest.

[323]  C. Page,et al.  Theophylline--an immunomodulatory role in asthma? , 1993, The American review of respiratory disease.

[324]  K. Chung,et al.  Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. , 1993, The Journal of allergy and clinical immunology.

[325]  M. Fujimura,et al.  Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. , 1993, Respiratory medicine.

[326]  G. Anderson.  Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol. , 1993, Agents and actions. Supplements.

[327]  C. Romanin,et al.  Potent block of Cl- channels by antiallergic drugs. , 1992, Biochemical and biophysical research communications.

[328]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[329]  W. R. Beam,et al.  Detection of alveolar macrophage-derived IL-1 beta in asthma. Inhibition with corticosteroids. , 1992, Journal of immunology.

[330]  A. Zwinderman,et al.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. , 1992, The New England journal of medicine.

[331]  T. Feizi,et al.  Immunoelectron microscopic studies reveal differences in distribution of sialo-oligosaccharide receptors for Mycoplasma pneumoniae on the epithelium of human and hamster bronchi , 1992, Infection and immunity.

[332]  R. Shaw,et al.  Dexamethasone-induced increase in platelet-derived growth factor (B) mRNA in human alveolar macrophages and myelomonocytic HL60 macrophage-like cells. , 1992, American journal of respiratory cell and molecular biology.

[333]  T. Haahtela,et al.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. , 1992, The Journal of allergy and clinical immunology.

[334]  P. Howarth,et al.  Early changes in T lymphocytes recovered by bronchoalveolar lavage after local allergen challenge of asthmatic airways. , 1992, The American review of respiratory disease.

[335]  G. Guyatt,et al.  A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[336]  P. Jeffery,et al.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. , 1992, The American review of respiratory disease.

[337]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[338]  N. Barnes,et al.  Trial of cyclosporin in corticosteroid-dependent chronic severe asthma , 1992, The Lancet.

[339]  T. Martin,et al.  Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. , 1991, The American review of respiratory disease.

[340]  C. Romanin,et al.  Immunologically activated chloride channels involved in degranulation of rat mucosal mast cells. , 1991, The EMBO journal.

[341]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[342]  A. Tattersfield,et al.  Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. , 1991, The American review of respiratory disease.

[343]  R. Dixon,et al.  Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). , 1991, The Journal of biological chemistry.

[344]  H. Kita,et al.  Regulation of Ig-induced eosinophil degranulation by adenosine 3',5'-cyclic monophosphate. , 1991, Journal of immunology.

[345]  L. Fabbri,et al.  Corticosteroid inhibition of airway microvascular leakage. , 1991, The American review of respiratory disease.

[346]  E. Juniper,et al.  Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. , 1991, The Journal of allergy and clinical immunology.

[347]  T. Out,et al.  Respiratory membrane permeability and bronchial hyperreactivity in patients with stable asthma. Effects of therapy with inhaled steroids. , 1991, The American review of respiratory disease.

[348]  A. Zwinderman,et al.  The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. , 1991, The American review of respiratory disease.

[349]  E. Juniper,et al.  Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. , 1990, The European respiratory journal.

[350]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[351]  J. Oates,et al.  Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[352]  P. Venge,et al.  Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. , 1990, The American review of respiratory disease.

[353]  M. Montminy,et al.  Regulation of camp-inducible genes by creb , 1990, Trends in Neurosciences.

[354]  H. Sasaki,et al.  Direct inhibitory action of glucocorticoid on glycoconjugate secretion from airway submucosal glands. , 1990, The American review of respiratory disease.

[355]  J. Shelhamer,et al.  Mechanisms by which glucocorticosteroids inhibit secretion of mucus in asthmatic airways. , 1990, The American review of respiratory disease.

[356]  P. Barnes,et al.  Effect of corticosteroids on airway hyperresponsiveness. , 1990, The American review of respiratory disease.

[357]  R. Dixon,et al.  Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis , 1990, Nature.

[358]  S. Peters,et al.  Arachidonic acid metabolism in normal human alveolar macrophages: stimulus specificity for mediator release and phospholipid metabolism, and pharmacologic modulation in vitro and in vivo. , 1990, American journal of respiratory cell and molecular biology.

[359]  S. Peters,et al.  An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. , 1989, The Journal of pharmacology and experimental therapeutics.

[360]  K. Chung,et al.  Effect of theophylline and adenosine on eosinophil function. , 1989, The American review of respiratory disease.

[361]  P. Godard,et al.  High doses of inhaled corticosteroids in unstable chronic asthma. A multicenter, double-blind, placebo-controlled study. , 1989, The American review of respiratory disease.

[362]  M. Robuschi,et al.  Inhaled frusemide is highly effective in preventing ultrasonically nebulised water bronchoconstriction. , 1989, Pulmonary pharmacology.

[363]  M. Hollenberg,et al.  Evaluation of the antiinflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I. , 1988, The Journal of clinical investigation.

[364]  N. Johnson,et al.  Effects of sodium cromoglycate and nedocromil sodium on histamine secretion from human lung mast cells. , 1988, Thorax.

[365]  G. Canonica,et al.  Theophylline and the immune response: in vitro and in vivo effects. , 1988, Clinical immunology and immunopathology.

[366]  P. Ghezzi,et al.  IL-1 induces IL-1. III. Specific inhibition of IL-1 production by IFN-gamma. , 1988, Journal of immunology.

[367]  B. Weeke,et al.  Fiberoptic bronchoscopy and bronchial mucosal biopsies in asthmatics undergoing long‐term high‐dose budesonide aerosol treatment , 1988, Allergy.

[368]  C. Salome,et al.  Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. , 1987, The American review of respiratory disease.

[369]  L. Lichtenstein,et al.  Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids. , 1986, Journal of immunology.

[370]  R. Naclerio,et al.  The pharmacologic control of mediator release from human basophils and mast cells. , 1986, Respiration; international review of thoracic diseases.

[371]  L. Rosenhall,et al.  High Dose Inhaled Budesonide in the Treatment of Severe Steroid‐Dependent Asthmatics , 1985, Allergy.

[372]  R. Pardi,et al.  Theophylline induced non specific suppressor activity in human peripheral blood lymphocytes. , 1985, Journal of immunopharmacology.

[373]  R. Naclerio,et al.  IgE-mediated leukotriene release in vitro and in vivo. , 1984, Transactions of the Association of American Physicians.

[374]  D. Cooper,et al.  Mycoplasma pneumoniae: acute illness, antibiotics, and subsequent pulmonary function. , 1984, Archives of disease in childhood.

[375]  O. Bruserud.  The effect of theophyllamine on T-lymphocyte activation in vitro. , 1984, Clinical immunology and immunopathology.

[376]  S. Peters,et al.  Arachidonic acid metabolism in purified human lung mast cells. , 1984, Journal of immunology.

[377]  S. Peters,et al.  Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. , 1983, The Journal of clinical investigation.

[378]  H. Simpson,et al.  Mycoplasma pneuminia infection. A follow-up study of 50 children with respiratory illness. , 1979, Archives of Disease in Childhood.

[379]  C. Shim,et al.  The effect of ethanol on the cough reflex. , 1973, Clinical science and molecular medicine.

[380]  A. Rebuck,et al.  STEROID‐SPARING EFFECT OF DISODIUM CROMOGLYCATE (“INTAL”) IN CHRONIC ASTHMA , 1969 .